Chief Strategy Officer, Sagar Anisingaraju, was quoted in a recent PharmaVOICE article discussing how to overcome the challenge of big data and AI’s relative “newness” within the pharma industry.
“A clinical neural network would mean research sharing across thousands of studies conducted in different therapeutic areas by different companies,” Mr. Anisingaraju says. “This is one area where collaboration and cooperation from multidisciplinary pharma companies and the technology vendors would have a long-standing impact for patients, as well as for the pharma industry.”